BioNTech Prepares First US Oncology Filing as ASCO Data Fleshes Out Late-Stage Pipeline

BioNTech to file its first US oncology BLA for BNT323 in 2026. The firm is advancing 13 pivotal trials with €16.8B in cash despite a transition in revenue.

BioNTech is within striking distance of a landmark moment. The company and its partner Duality Biologics plan to submit a Biologics License Application (BLA) to the US Food and Drug Administration later this year for the antibody-drug conjugate Trastuzumab Pamirtecan (BNT323). The candidate already carries Fast Track and Breakthrough Therapy designations for endometrial cancer, backed by a Phase 2 study that delivered a confirmed objective response rate of 47.9% and a median progression-free survival of 8.1 months. A separate application is already under review with China’s NMPA. A successful US filing would mark BioNTech's first oncology approval on American soil.

The buzz around the ASCO annual meeting in Chicago served as a staging ground for a broader pipeline push. BioNTech now has 13 pivotal trials underway, with a target of 15 by the end of 2026 — more than double the count from two years ago. Among the most compelling data sets was a randomized Phase 3 study, BNT324-03, targeting metastatic castration-resistant prostate cancer. The trial will enroll roughly 736 patients who have already received one or two androgen receptor inhibitors, pitting the ADC BNT324 directly against the standard chemotherapy docetaxel. Early numbers were striking: a confirmed objective response rate of 42.3% and a median radiographic progression-free survival of 11.3 months in heavily pretreated groups, justifying the leap into a decisive stage of testing.

ASCO also showcased strategic recalibrations. BioNTech and partner Bristol Myers Squibb shifted the primary endpoint of their Phase 3 ROSETTA Lung-02 study for the bispecific antibody Pumitamig from overall survival to progression-free survival. The move allows a faster path to regulatory submission in the hotly contested PD-(L)1×VEGF bispecific space, avoiding the long wait for mature survival data. Pumitamig has now produced three consistent data sets — including positive reads in small-cell lung cancer and triple-negative breast cancer — and its head-to-head Phase 3 trial pits Pumitamig plus chemotherapy against pembrolizumab plus chemotherapy in first-line NSCLC. Separately, the CTLA-4 antibody Gotistobart, developed with OncoC4, showed durable activity in heavily pretreated patients with platinum-resistant ovarian cancer, with clinically meaningful overall survival.

Financially, BioNTech is navigating the transition from a Covid-19 revenue stream to an oncology powerhouse. The company reported €16.8 billion in cash and securities as of March 31, 2026, and is simultaneously executing a share buyback program of up to $1 billion over 12 months. But the revenue outlook for 2026 has been set at €2.0 billion to €2.3 billion, down from €2.9 billion the prior year. First-quarter results underscored the pressure: a net loss of €531.9 million, translating to a loss of €2.10 per share.

The stock has yet to fully reflect the pipeline transformation. Shares closed at €82.35, 19% below the 52-week high of €101.90 and down nearly 17% year-to-date. However, Friday’s session brought a gain of 2.68%, nudging the stock back above its 50-day moving average. A consensus of 17 analysts rates the shares a “Buy” with a price target of roughly $125 — implying upside of around 38% from current levels.

Investors now have two concrete catalysts to watch. The BLA submission for Trastuzumab Pamirtecan remains the most imminent, while second-quarter results are scheduled for August 4. With seven late-stage data readouts planned for 2026, the summer months will test whether ASCO’s clinical signals can translate into lasting market momentum.